Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.37 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.37 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.37 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.37 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.37 |
| ▸ | CHRNG | P07510 | 1/20 | 0.37 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.37 |
| ▸ | CHRND | Q07001 | 1/20 | 0.37 |
| ▸ | FURIN | P09958 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | FAP | Q12884 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25615822 | 0.98 | SIRT5 (0.41) | SIRT5SIRT2SIRT1SIRT3CHRNA1 | |
| SCHEMBL18823533 | 0.96 | CHRNA1 (0.38) | SIRT5SIRT2SIRT1SIRT3MAP1LC3B | |
| SCHEMBL25000070 | 0.93 | SIRT2 (0.38) | SIRT5SIRT2SIRT1SIRT3MAP1LC3B | |
| SCHEMBL20616683 | 0.93 | SIRT5 (0.38) | SIRT5SIRT2SIRT1SIRT3MAP1LC3B | |
| SCHEMBL20616684 | 0.93 | SIRT5 (0.38) | SIRT5SIRT2SIRT1SIRT3MAP1LC3B | |
| SCHEMBL25826705 | 0.92 | FURIN (0.37) | SIRT5SIRT2SIRT1SIRT3MAP1LC3B | |
| SCHEMBL18823291 | 0.92 | SIRT2 (0.41) | SIRT5SIRT2SIRT1SIRT3FURIN | |
| SCHEMBL19687790 | 0.92 | SIRT5 (0.39) | SIRT5SIRT2SIRT1SIRT3MAP1LC3B | |
| SCHEMBL18823292 | 0.92 | SIRT2 (0.41) | SIRT5SIRT2SIRT1SIRT3FURIN | |
| SCHEMBL15699830 | 0.92 | SIRT5 (0.39) | SIRT5SIRT2SIRT1SIRT3MAP1LC3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11135307-B2 | Peptide-containing linkers for antibody-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-20190241649-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9943609-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-9872918-B2 | Hydroxyl-polymer-drug-protein conjugates | MERSANA THERAPEUTICS, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-9770519-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241649-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | SIRT5 2313/4885SIRT2 2841/4885SIRT1 2541/4885 |
| US-11135307-B2 | Peptide-containing linkers for antibody-drug conjugates | CD2BP2, DNPEP, LNPEP | SIRT5 3290/4885SIRT2 3975/4885SIRT1 4075/4885 |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | SIRT5 3290/4885SIRT2 3975/4885SIRT1 4075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.